News Column

Proteome Sciences Publishes Study For Alzheimer's Blood Test

July 8, 2014

Hana Stewart-Smith

LONDON (Alliance News) - Shares in Proteome Sciences PLC rose Tuesday morning after it published a study, along with King's College London, identifying proteins that could be used to predict the onset of Alzheimer's, in a step towards developing a blood test for the disease.

Shares in Proteome were trading up 12% at 37.10 pence Tuesday morning.

The study was published in 'Alzheimers & Dementia: The Journal of the Alzheimer's Association', as part of a collaboration funded by Alzheimer's Research UK, the UK Medical Research Council, the National Institute for Health Research Maudsley Biomedical Research Centre and Proteome Sciences itself.

Using data from three international studies, it took blood samples from a total of 1,148 individuals and analysed them for 26 proteins that had previously shown a connection to Alzheimer's.

From this study, the company identified 10 proteins capable of predicting whether patients with mild cognitive impairment would develop Alzheimer's within a year, which it said has an accuracy of 87%.

Proteome said that it was selecting commercial partners to combine these protein biomarkers in a blood test for the global market.

The company said the study was a "major advance" in developing a blood test for the disease, and such a test would be easier and less expensive than using brain imaging or cerebrospinal fluid.

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Alliance News

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters